{"id":"NCT00535782","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis","officialTitle":"A Mechanism of Action Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) on Lipids, Arterial Stiffness, and Markers of Atherogenic Risk in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10-31","primaryCompletion":"2008-09-30","completion":"2011-01-31","firstPosted":"2007-09-26","resultsPosted":"2012-11-14","lastUpdate":"2017-07-26"},"enrollment":132,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tocilizumab","otherNames":["RoActemra","Actemra"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Methotrexate","otherNames":[]}],"arms":[{"label":"TCZ + MTX","type":"EXPERIMENTAL"},{"label":"Placebo + MTX","type":"PLACEBO_COMPARATOR"}],"summary":"This 2 arm study will investigate the effects of tocilizumab on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe active rheumatoid arthritis. In Part 1 of the study, patients will be randomized to receive either tocilizumab 8mg/kg intravenously or placebo every 4 weeks, in combination with methotrexate 7.5-25 mg weekly. In Part 2, all patients will receive open-label treatment with tocilizumab plus methotrexate.","primaryOutcome":{"measure":"Change From Baseline in Small Low Density Lipoprotein (sLDL) Particle Numbers","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"TCZ + MTX","deltaMin":737.79,"sd":467.097},{"arm":"Placebo + MTX","deltaMin":792.78,"sd":392.051}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":40,"countries":["United States","Canada","Puerto Rico","United Kingdom"]},"refs":{"pmids":["22491018"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":70},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Diarrhoea","Bronchitis","Rheumatoid arthritis"]}}